Severe XXXX induced by a combination of @entity5119 and @entity12880 .

@entity1 @entity20124 @entity753 @entity12880 @entity5704 @entity2204 @entity1674 @entity9680 @entity4741 @entity1675 @entity5119 @entity165
Observation of a markedly depressed HDL- @entity165 (5 mg/dL) in a @entity1 with @entity753 ( @entity753 ) receiving @entity5119 (1 g/day) and @entity12880 (2 g/day) prompted a review of all cases treated by this combination at our lipid clinic. @entity9680 (HDL-C less than 15 mg/dL) developed in 19 of 28 (70%) hyperlipidemic subjects who received this combination for an average of 1.5 years. This effect was sustained and reversible; it did not occur on either drug alone and was manifested on average 17 weeks after the combination was started. Plasma @entity1674 increased significantly in most of those @entity1 susceptible to this reduction in HDL-C. Plasma @entity1675 was decreased 82%, in proportion to the HDL-C fall, whereas apo @entity5704 was lowered 65%. Since apo C-III concentrations tended to be high, the apo A-I/C-III ratio was markedly depressed. @entity2204 levels were unchanged and apo B levels reflected the high LDL concentrations of the underlying disease. An intermediate response was observed in subjects whose HDL-C remained well above 15 mg/dL on the combination. No deleterious side-effects could be attributed directly to the administration of the combined drugs in this high-risk group. One @entity1 actually showed complete regression of xanthelasma and extensor @entity4741 of the finger on the combination. A parallel is drawn with @entity20124 and the presence of the @entity1675 Milano variant, where similar HDL-C levels are observed in the absence of an increased atherogenic risk. It is mandatory to monitor plasma HDL-C in @entity753 @entity1 treated with this combination, otherwise the pronounced @entity9680 could go unnoticed.
